Stephens Inc Castle Biosciences Inc Transaction History

Stephens Inc

$6.77 Billion
Q3 2024

A detailed history of Stephens Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Stephens Inc holds 15,095 shares of CSTL stock, worth $418,433. This represents 0.01% of its overall portfolio holdings.

Number of Shares

15,095

Previous 23,773 36.5%

Holding current value

$418,433

Previous $517,000 16.83%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$17.4 - $31.47 $150,997 - $273,096	-8,678 Reduced 36.5%	15,095 $430,000
Q2 2024 Aug 06, 2024	SELL	$18.84 - $24.94 $206,505 - $273,367	-10,961 Reduced 31.56%	23,773 $517,000
Q1 2024 May 15, 2024	SELL	$18.06 - $25.3 $159,740 - $223,778	-8,845 Reduced 20.3%	34,734 $769,000
Q4 2023 Feb 13, 2024	SELL	$12.19 - $22.43 $650,604 - $1.2 Million	-53,372 Reduced 55.05%	43,579 $940,000
Q3 2023 Nov 14, 2023	SELL	$13.28 - $20.3 $145,376 - $222,224	-10,947 Reduced 10.15%	96,951 $1.64 Million
Q2 2023 Aug 14, 2023	BUY	$11.66 - $26.0 $383,369 - $854,854	32,879 Added 43.83%	107,898 $1.48 Million
Q1 2023 May 15, 2023	BUY	$19.47 - $28.49 $416,404 - $609,315	21,387 Added 39.88%	75,019 $1.7 Million
Q4 2022 Jan 25, 2023	BUY	$18.08 - $30.0 $160,134 - $265,710	8,857 Added 19.78%	53,632 $1.26 Million
Q3 2022 Nov 02, 2022	SELL	$22.51 - $34.32 $16,319 - $24,882	-725 Reduced 1.59%	44,775 $1.17 Million
Q2 2022 Aug 03, 2022	BUY	$16.0 - $45.99 $728,000 - $2.09 Million	45,500 New	45,500 $999,000

Others Institutions Holding CSTL

# of Institutions

201

Shares Held

24.5M

Call Options Held

303K

Put Options Held

30.3K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $729M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Account